Copper as a Target for Treatment of Neuroblastoma: Molecular and Cellular Mechanisms by Urso, Emanuela & Maffia, Michele
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 12
Copper as a Target for Treatment of Neuroblastoma:
Molecular and Cellular Mechanisms
Emanuela Urso and Michele Maffia
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/55423
1. Introduction
1.1. Copper and carcinogenesis, a double-edged sword
Copper is a trace metal essential to the catalysis of a wide range of enzymatic activities,
including those involved in the process of energy production (cytochrome c oxidase), the cell
response to oxidant injuries (Cu,Zn-superoxide dismutase), the catecholamine (dopamine β-
monooxygenase) and melanin (tyrosinase) production, the remodelling of extracellular matrix
(lysyl oxidase), blood clotting processes (Factors V and VIII) and iron metabolism (ceruloplas‐
min and hephaestin) [1]. The catalytic properties of copper are linked to its ability to easily
assume the oxidized (Cu2+) and reduced (Cu+) states, but just the metal reactive behaviour can
trigger severe cell alterations through the generation of hydroxyl radicals in Fenton-like
reactions [2,3]. When the cytosolic copper concentration is above the optimal level, the newly
formed reactive oxygen species (ROS) rapidly bind to DNA, thus inducing the breaking of the
nucleic acid strands and initiating a series of cascade events that can lead to significant damage
to cell structures and function [4].
Considerable intrinsic oxidative stress and enhanced serum and tissue copper levels depict a
disease condition that often accompanies the progression of several tumour forms, in turn
resulting from a perturbed energy metabolism, mitochondrial dysfunction, release of cyto‐
kines and inflammation [5]. Copper is intimately involved in all these cell functions, thus
targeting the elevated copper levels would be an ideal therapeutic strategy to effectively
counteract the tumour development [5].
This issue is anyway highly debated. In fact, the topical delivery of copper complexes to
tumour tissues has been demonstrated to kill the cancer cells through a “therapeutic” induction
of oxidative stress [6]. At the same time, especially in the case of solid tumours, as neuroblas‐
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toma, copper is directly involved in the spread of the primary tumour, mainly through the
stimulation of tumour angiogenesis [6]. It follows that targeting the tumour copper content to
limit the cancer aggressiveness requires a comprehensive knowledge of the cell metal man‐
agement under the disease state. Here, the multifaceted contribution of copper to the patho‐
physiology of neuroblastoma will be dissected, with special attention paid to the regulation
of membrane copper transporters and their role in sustaining the cancer spread. To make the
reader familiar with the main copper transport systems in mammalian cells, a short description
has been provided in Box 1.
2. Neuroblastoma and Copper: A complex relationship
Neuroblastoma is the most common pediatric extra-cranial neoplasm [7], whose malignant
form accounts for about a 50% of cancer mortality in chemoradiotherapy-treated subjects [8].
The aggressiveness of advanced-staged neuroblastomas is notoriously associated with the N-
myc oncogene amplification, which translates in a strong expression of a pleiotropic transcrip‐
tion factor, responsible for the rich tumour vasculature, the metastatic behaviour, and the
chemotherapy resistance [9-11]. Thus, N-myc overexpression is a well-known adverse prog‐
nostic factor [12]. Interestingly, the degree of N-myc oncogene amplification in neuroblastoma
cells has been put in relation to the trace metal cell content (iron, copper, zinc) in both cultured
neuroblasts and murine xenografts [13-15]. In particular, the number of N-myc oncogene copies
has been demonstrated to proportionally correlate with the neuroblastoma copper content.
This finding, together with evidences from the literature, lets us suppose that copper accu‐
mulation strictly determines the neuroblastoma invasiveness. Plausible mechanisms under‐
lining the copper dependence of neuroblastoma metastasis are both direct/specific, and
mediated by the metal-induced accumulation of ROS.
Referring to the latter category of mechanisms, an in vitro study in 31 subjects affected by
advanced neuroblastoma revealed an elevated activation of specific tissue matrix metallo
proteinases (MMP-2 isoform) and the reduced expression of their specific inhibitors (TIMP-2)
[16], that can be associated with copper-induced oxidative stress [17]. In this regard, we observe
that metallo proteinases are secreted by tumour cells and facilitate the cancer dissemination
by the degradation of the extracellular matrix.
The high copper levels detected in neuroblastoma can at least partly confer a growth advantage
to the tumour cells by metal specific pathways. Significantly, copper acts as a cofactor for the
cytochrome c oxidase enzyme that allows the conversion of cytosolic ferric ion into the ferrous
form, subsequently incorporated into ferritin, the most important iron storage protein. Iron-
complexed ferritin is then secreted by cancer cells, so enriching the serum protein pool. The
importance of this copper/iron antagonism is evident if we consider that neuroblastoma
patients with high ferritin levels undergo a bad prognosis [18].
Given the complexity of the copper-neuroblastoma relationship, in order to guide the reader
through the text, we observe that the lines of copper intervention in neuroblastoma progression
can be substantially subdivided as follows:
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i. cancer energy metabolism
ii. tumour vascularization
Copper transport systems are gaining growing importance in the studies about the various
aspects of the metal role in neuroblastoma, so the peculiar expression pattern will be described
before discussing the pathological topics.
3. Copper transport systems in neuroblastoma cells: Regulation and
physiopathological implications
Copper critically regulates the degree of neuroblastoma growth and microvascularization,
which determines the tumour aggressive phenotype [19,20]. The importance of this metal is
emphasized by the strong presence of specific transport proteins in neuroblastoma cells, that
testifies to a lively management of tumour copper stores. Highly variegated mechanisms of
regulation of copper homeostasis have been specifically reported for neuroblastoma (some of
them reviewed here), that make it difficult to establish the nature of copper involvement: is
the ion metabolic disruption a cause or an effect?
Copper import. It is widely believed that copper import in neuroblastoma cells is mediated by
hCtr1 [21]. However, recent work from our laboratory in an in vitro neuroblastoma cell model
has enlightened a role for the cellular prion protein PrPC in mediating the high affinity copper
intake, upon normal metal availability [22]. In addition, we demonstrated that copper
shortness induces an up-regulation of PrPC expression in a neuroblastoma cell model, a cell
adaptive strategy aimed at restoring the standard copper status [23].
In support of its involvement in tumorigenesis, the PrPC expression is up-regulated in nervous
tissues affected by hypoxia, a condition typically occurring during the growth of a solid tumour
[24]. The reader is referred to paragraphs 4.2 and 6.2 for a detailed account of the PrPC functions
in the tumour spread.
Copper efflux. The ATP7A copper ATPase (full length 170 KDa protein) is strongly expressed
by neuroblastoma cell lines [21,23] and subjected to an articulated copper-dependent regula‐
tion.
In many cell types this efflux pump delivers copper to the secretory compartments and, when
copper should accumulate inside the cytosol, it traffics toward the cell periphery to export the
ion excess [25]. However, peculiar regulative mechanisms have been documented in neuro‐
blastoma models.
In fact, it has been demonstrated in the M17 neuroblastoma cell line that fluctuating copper
levels (excess/starvation) in the cell microenvironment can favour the interaction of ATP7A
proteins with clusterins (apolipoprotein J), the last ones targeting the pumps toward degra‐
dation through the lysosomal pathway [26]. This copper-regulated clusterin function may have
multiple implications, if we consider that a recent study on neuroblastoma cell lines, mouse
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models, and human specimens evidenced that this molecular chaperon behaves as a tumour
and metastasis suppressor, negatively regulated by N-myc in the most aggressive forms [27].
In our opinion, the copper-clusterin link deserves further exploration in the light of the
reported elevation in copper neuroblastoma content observed in N-myc amplified tumours.
If N-myc really down-regulates clusterin (still controversial aspect), one would expect an
increase in copper export function and so an overall reduction of the ion cancerogenic action.
This evidently contradicts the N-myc - tumour malignancy binomial association (where copper
should exert a prominent role) and minimizes the contribution of clusterin to the copper-
dependent tumour progression. In fact, considering that N-myc elevates the neuroblastoma
copper content, one can suppose that the cytosolic copper lowering due to a down-regulated
expression of clusterin is overridden by other cell mechanisms causing the increase of cancer
copper levels.
Copper uptake 
 
Ctr1 (Copper transporter 1). High-affinity Cu+  importer, composed of three main domains: an 
extracellular N-terminal tail containing multiple copper-binding methionine residues; a trans-
membrane segment consisting of three α-helical regions; an intracellular C-terminal domain. Three 
subunits assemble to form a homo-trimeric channel (9 Å pore diameter) within the plasma 
membrane (see [118] for a review). 
 
Ctr2 (Copper transporter 2). Copper permease, whose structure resembles that of Ctr1. 
Predominantly localized to endosomes and lysosomes, it seems to provide a mechanism of copper 
recycling from degraded cuproenzymes [119]. 
 
PrPC (Cellular Prion protein). Endogenous copper-binding glycoprotein, mainly expressed in the 
central nervous system. The protein structure includes an unstructured N-terminal domain and a C-
terminal globular region composed of three α -helices and two short beta-strands. When Cu2+ ions 
bind to the N-terminal octapeptide repeats (residues 51–90), the protein undergoes endocytosis, that 
providing a route for cell copper entry [58,59].  
 
Cytosolic transport 
 
CCS. Metallo chaperone required for copper delivery to Cu,Zn Superoxide dismutases 1; up-
regulated in response to copper deficiency [120]. 
 
Cox17. Metallo chaperone delivering copper to Sco1 and Cox11 proteins in order to catalyse the 
cytochrome c oxidase copper loading [121]. 
 
Atox1. Metallo chaperone that delivers copper to ATP7A and ATP7B Cu+ efflux pumps [122]. 
 
Metallothioneins. Small cysteine-rich proteins tightly binding copper ions and buffering the ion 
excess [123]. 
 
Copper efflux 
 
ATP7A. Cu+-transporting P-type ATPase expressed by all cell types, with the exception of liver. 
Structural features include eight membrane-spanning domains and six N-terminal cysteine-rich 
metal binding motifs (MXCXXC) [25]. 
Box 1. Main proteins involved in cell copper homeostasis
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Coming back to main focus of this paragraph, multiple ATP7A spliced variants can be retrieved
in human cells, not necessarily related to disease states, with a cell type-specific expression
pattern. The expression of a 11.2 KDa splicing product (103 amino acids) has been reported in
SY5Y neuroblastoma cells, harbouring a sequence able to bind copper ions [28]. It has been
proposed that such spliced product can work as a copper chaperon to direct the cytosolic
copper toward the nuclear compartment.
Intracellular copper distribution. Among copper chaperons, the contribution of COMMD1
(Copper Metabolism MURR1 Domain containing 1) to the copper status in neuroblastoma cells
is an unexplored issue so far. However, some inputs from the recent scientific literature let us
hypothesize an involvement.
Endogenous COMMD1 expression has been reported in the SH-SY5Y neuroblastoma cell line,
together with the isoform 3. A punctate cytoplasmic distribution, denser in the perinuclear
region, has been shown for COMMD1, while COMMD3 appears more diffused [29]. The role
of COMMD1 in neuroblastoma progression is potentially articulated on multiple levels of
action, even if direct demonstrations are missing and the following dissertation aims at
enlightening some aspects of copper-dependent regulation of the protein fate.
A role in preventing tumour growth and metastasis has been proposed for COMMD1, based
on its ability to repress the NF-KB pathway and the HIF1α/β dimerization and so inhibit the
expression of genes involved in tumour angiogenesis [30]. However, as documented in N2a
neuroblastoma cell line, upon copper excess, COMMD1 can form a hetero-complex with CCS
and SOD1, leading to decreased levels of SOD1 dimers and subsequently reduced anti-oxidant
activity [31]. In other words, in the presence of high copper, the COMMD1 cell fate can
potentially assume a negative connotation.
COMMD1 is also an interacting partner of ATP7A proteins and, analogously to clusterin, can
drive their degradation through a proteasomal pathway [32], this indicating a further contri‐
bution of this chaperon to the neuroblastoma copper content. However, knowledge about
these aspects is still limited.
The COMMD1 involvement in determining the neuroblastoma copper condition is strictly
linked to the protein XIAP (X-linked inhibitor of apoptosis). XIAP protective action is due to
the prevention of the activation of a subset of cell death proteases (caspases 3, 7 and 9) [33,34],
and inhibiton of Fas- [35] and Bax-induced apoptosis [33].
During the last decade, a role for XIAP in controlling the cell copper homeostasis has been
described [36]. In fact, the overexpression of XIAP protein (not transcript) selectively reported
in chemotherapy-resistant neuroblastomas, but no other tissues [37], may indicate the
occurrence of a particular copper status. XIAP is a copper-binding protein that, in the olo-form,
favours the ubiquitination and degradation of COMMD1, that in turn interacts with ATP7A
to support copper excretion [36]. Where overexpressed, it is reasonable to presume a subse‐
quent consistent reduction of COMMD1 cytosolic protein levels, and so an increase of the
cellular copper content.
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However, the binding of copper to XIAP negatively impacts the protein stability, so a negative
feedback exists [38]. In the case of chemotherapy-resistant neuroblastomas, the protein overex‐
pression probably overcomes the effects deriving from copper-driven XIAP inactivation.
Preclinical evidences of the importance of XIAP as a target to treat neuroblastoma have been
recently collected, all based on the lowering of the threshold for the induction of apoptosis
through the depression of XIAP expression. The use of Thymoquinone, a bioactive compound
from nigella sativa, has been shown to selectively down-regulate XIAP in neuroblastoma cells,
but not in normal neuronal cells, with an expected higher copper efflux [39]. Smac (Second
mitochondria-derived activator of caspase) mimetics (e.g. LBW242) have been reported to
sensitize chemotherapy resistant and XIAP-overexpressing neuroblastomas, by favouring the
degradation of XIAP and TNF-α expression [37].
4. Copper-dependence of neuroblastoma metabolic changes
The oxygen partial pressure within a solid tumour ranges from 5-10 mmHg in highly vascu‐
larized regions to absence (anoxia) around the necrotic areas [40,41]. Most cancer cells tend to
adapt to the intra-tumour hypoxic microenvironment by activating a pro-survival signalling,
a pro-angiogenic pattern of gene expression and through the metabolic switching from the
oxidative phosphorylation to the glycolytic pathways (Warburg effect) [42].
Currently, there is not a homogeneous view on the causative events, but two major factors are
usually indicated as responsible, the Hypoxia-Inducible Factors 1 and 2 (HIF1,2), and p53
transcription factor.
HIF1 and 2 are heterodimeric basic helix-loop-helix-PAS domain transcription factors,
composed of a constitutively expressed β subunit and a α regulatory subunit (HIF1α/2α),
whose expression is induced by hypoxia, cancer-associated mutations, or inflammatory
cytokines [43,44].
HIF-1α and HIF-2α are major actors in the cell adaptive response to hypoxic conditions and
control the expression of distinct, but functionally converging genes [45]. Each cell type
exhibits a peculiar profile of HIF-1α and 2α expression and their functions may also differ. In
the case of neuroblastoma, at a careful analysis of the expression pattern, tumour stage, and
copper status, it can be observed that copper heavily influences the response to hypoxia and
that the tumour progression and the evolution of copper metabolism go hand in hand.
4.1. HIF-1α
HIF-1α, but not HIF-2α, is preferentially expressed and up-regulated by moderate hypoxia in
N-myc amplified neuroblastoma cell lines and primary tumours, correlating with a poor
prognosis [41,46]. In the light of the linear increase of copper neuroblastoma levels with the
degree of N-myc gene amplification and the proven role of Cu2+ ions in stabilizing the structure
of the HIF-1α subunit [47], it can be deduced that copper plays in key role in inducing the
neuroblastoma metabolic changes.
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Cu2+ ions determine the structural stabilization of the HIF-1α subunit (oxygen-sensitive)
through the inhibition of prolyl-4-hydroxilases, which allow the subsequent ubiquitination
and degradation of such factor [47].
Interestingly, by this way Cu2+ indirectly promotes the synthesis of ceruloplasmin, a plasma
and liquor copper chaperon with a ferroxidase activity, whose expression is typically under
HIF-1 control [48]. Being ceruloplasmin a major copper vehicle, such mechanism can be
interpreted as cancer “self-nourishing”. It must be added that HIF-1 target genes also include
VEGF (Vascular Endothelial Growth Factor), a recognized chemotactic and mitogen factor [49],
and VEGFR-1 (VEGF Receptor-1) [50], both involved in the positive regulation of the sprouting
of blood vessels within the primary tumour.
Further, White et al. (2009) demonstrated that the up-regulation of the hypoxia inducible factor
HIF-1α causes the selective distribution of copper ions to the secretory pathway. They
observed in tumour-associated macrophages that the hypoxic stress can influence the intra‐
cellular distribution of copper ions, determining an increased ion entry through the high
affinity channel Ctr1 and then an elevated efflux through the ATP7A pump [51].
All these experimental evidences underline the prominent role of copper in sustaining the
HIF-1α-dependent adaptation to hypoxia in N-myc amplified neuroblastomas, as well as the
hypoxia-stimulated activation of copper transport activities.
4.2. HIF-2α
HIF-2α, but not HIF-1α, has been shown to be highly expressed in neuroblastoma vascularized
areas, and this pattern seems to be associated with an unfavourable patient outcome, due to
the occurrence of distal metastasis [41]. In addition, a small subset of neuroblastoma cells
strongly HIF-2α-positive has been described, which could represent the cancer stem cells [52].
To our knowledge, no precise data are available about the copper-dependent activity/
activation of HIF-2α, however some molecular evidences collected in other cell models
strongly point at a potential existence of such a link.
As an example, Menkes copper ATPase (Atp7a) gene expression has been demonstrated to be
strongly induced by HIF-2α in mammalian intestine [53]. HIF-2α has been also demonstrated to
induce the expression of DMT1 and Ctr1 (by about 25%) copper importers in human intestinal
cells, so determining a parallel increase (fivefold) in the processes of cellular copper uptake [54].
These findings confirm that, independently on the involvement of HIF-1α or HIF-2α, tumour
hypoxia activates a series of processes functional to distribute copper toward the secretory
pathway (enzyme-complexed) or make it available in the extracellular medium. Here, copper
may function as a signalling molecule and sustain the angiogenic processes, essential to the
neuroblastoma growth.
The scientific literature also suggests that the HIF-2α prolonged response to hypoxia can be
alternatively mediated by a high affinity copper-binding protein, namely the cellular prion
protein PrPC [55] (Box 1). Accordingly, the PrPC expression degree is elevated in hypoxic
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nervous tissues [56], and its overexpression has been shown to confer a highly invasive
phenotype to tumour cells [55,57].
By virtue of a direct involvement of PrPC in the cell copper import [22,58,59], an elevated
protein expression under hypoxia could represent a cancer cell strategy to assure the neuro‐
blastoma growth through the enhanced copper intake [23]. In fact, copper stimulates neuro‐
blastoma cell proliferation [60].
Interestingly, although it has been demonstrated that the up-regulation of PrPC in human
colorectal carcinoma cells induces the glucose transporter-1 (Glut-1) expression and a subse‐
quent increase in the glycolytic rate via Fyn-HIF-2α pathway [55], the transfection of a plasmid
expressing wild-type HIF-2α in N-myc amplified neuroblastoma cells has been demonstrated
to be marginally involved in the regulation of glycolytic genes [46]. Surprisingly, notwith‐
standing a rise in Glut-1 expression, the glucose influx was not increased [46].
Conclusively, to reinforce the concept of an autonomous cancerogenic role of copper, it can be
observed that elevated HIF levels have been observed even under normoxic conditions,
meaning that other factors than hypoxia, e.g. copper, can sustain the aerobic glycolysis and
induce the expression of HIF-targeted genes.
4.3. p53
p53 transcription factor is a key tumour suppressor protein, whose functions contribute to
prevent cancer progression. Mutated p53 gene products or defects in the integration of proteins
with which p53 is connected, are associated with the malignant progression of the majority of
human tumours [61]. Neuroblastoma rarely shows mutated p53 at diagnosis, thus therapies
result effective at first. However, gene mutations, p53 cytosolic sequestration, or deregulated
p53/MDM2 (ubiquitin protein ligase -E3- for p53) pathways have been reported during
neuroblastoma relapses or therapies, thus conferring high-level multidrug resistance [62-65].
Loss of p53 function seems to impair the efficiency of mitochondrial respiration by hampering
the insertion of copper ions as cofactors into the cytochrome c oxidase enzymatic complex [66].
That would cause the switching from cell respiration to aerobic glycolysis (Warburg effect),
typical metabolic change observed in cancer cells.
In detail, p53 directly regulates the expression of the SCO2 (Synthesis of Cytochrome c
Oxidase) gene, coding for a protein that facilitates the copper delivery to the subunit II of
cytochrome c oxidase, determining the assembly of the enzymatic complex [66].
As suggested in [67], given the essential role of copper in determining the Warburg effect in
cancer cells, it cannot be excluded that deregulated p53 pathways may affect the expression
or function of other proteins involved in cell copper acquisition and utilization.
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5. Copper promotes the neuroblastoma survival and growth by sustaining
the anti-oxidant enzyme activities
Cutting copper supply can represent a valuable therapeutic strategy for neuroblastoma, as the
induced mitochondrial impairment and oxidative stress can make neuroblastoma cells
vulnerable. Accordingly, even under unstressed environment, mitochondria in this cell type
exhibit a high rate of protein oxidation, this indicating a consistent susceptibility to the
oxidative injury [68,69]. The positive connotation of a drop in the neuroblastoma cell copper
content has been demonstrated and emphasized by a rich literature showing that copper
chelation (triethylene tetramine tetrahydrochloride) can effectively promote the apoptosis of
neuroblastoma cells [70,71].
Here follow some argumentations from the literature around the negative impact of copper
starvation on neuroblastoma cell survival, extrapolated from in vitro preclinical studies.
SH-SY5Y neuroblastoma cells have been widely used as a model to dissect the molecular basis
of the tumour sensitivity to copper.
In particular, the continuous exposure (up to three passages) of SH-SY5Y neuroblastoma cells
to the copper-chelating agent Trien has been demonstrated to induce the expression of
antioxidants and a 40% apoptotic cell loss at the end of the third passage [70]. Copper has been
shown to be important in keeping a critical level of ATP. In fact, the relevant Cu,Zn SOD and
cytochrome c oxidase activities were reduced by, respectively, 80 and 68% [70]. Another report
has confirmed these findings, indicating that copper starvation by Trien impairs the antioxi‐
dant defences of neuroblastoma cells, with obvious implications with respect to the therapeutic
inhibition of the tumour growth [71].
Arciello et al. (2011) further characterized the effects of Trien treatment in SH-SY5Y neuroblasto‐
ma cells [72]. SOD1 (cuproenzyme) expression decline was associated with a reduction of the
enzyme activity, mainly due to copper shortness rather than to a decreased protein expression. In
fact, copper replenishment was able to reactivate the apo-form of the enzyme, in agreement with
previous observations [73]. Copper depletion also favoured the entrance of the SOD1 apo-form
(not metallated) into the mitochondria [72], where it was retained due to a partial unfolded and
obviously inactive configuration. The authors also observed an increased expression of CCS (Box
1), finalized to optimize the copper intracellular distribution [72].
It the light of these findings, it can be observed that the neuroblastoma commitment to the
apoptotic death was not due to an irreversible mitochondrial damage, even considering that
the loss of the mitochondria-associated SOD1 was much less evident than observed for the
cytosolic one [72]. However, it is plausible that the absence of copper prevented SOD1 from
counteracting the oxidative-mediated damage to mitochondrial proteins [74]. Accordingly, it
has been shown that brain tissues exhibit a SOD1 localization inside the mitochondrial matrix
with an antioxidant function [75].
In our laboratory we analysed the anti-oxidant response to copper starvation in a rat neuro‐
blastoma model (B104), investigating in parallel the expression of copper membrane trans‐
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porters [23]. A significant increase of caspase-3 activity was detected in copper-starved cells,
indicating the activation of a cell death program through the induction of oxidative stress. In
agreement, the total Cu,Zn SOD activity resulted half-reduced with respect to normal condi‐
tions, as expected in consideration of the role of copper as a cofactor [23]. Interestingly, the
cellular prion protein expression in copper-starved neuroblastoma cells was heavily induced.
This finding was reconsidered in the light of a rich literature showing that the 64Cu loading
and the enzymatic activity of Cu,Zn SOD from the brain of P-rnp 0/0 mice result 10-50% reduced
with respect to the wild-type genotype [76-78].
A special attention has been dedicated to the adaptive response actuated by PrPC, that is
physiologically and consistently localized on the outer surface of neurons at synapses and
gliocytes [79,80]. Under normal conditions, PrPC binds copper ions with high specificity and
affinity (femto- to nanomolar range), by the repeated sequences present on its N-terminal
region. By virtue of this property and the ability to undergo endocytosis upon copper binding,
PrPC is believed to drive the cellular copper intake [22,58,59].
The up-regulation of PrPC upon copper limitation has been interpreted as a compensatory
mechanism to re-establish the standard cell copper status through a direct transport activity.
It has been also demonstrated to be responsible for the ability of copper-starved cells to almost
completely recover the SOD enzyme function upon re-exposure to standard growth condi‐
tions. The authors conclusively demonstrated that the PrPC neuroprotective action in neuro‐
blastoma cells is due to its ability to translocate copper ions into the cytosol. Here, they can act
as cofactors in Cu,Zn SOD activation [23].
6. Critical role of copper transporters in neuroblastoma vascularization and
spread
Most pro-angiogenic factors implicated in neuroblastoma progression need copper to properly
work or exert their own functions by activating copper-dependent pathways and enzymes.
The best known pro-angiogenic mediator, namely the Vascular Endothelial Growth Factor
(VEGF), has been demonstrated to be overexpressed in high-risk neuroblastomas at the time
of diagnosis and to be a bad prognostic marker [81]. The elevated copper levels detected in
malignant neuroblastoma are expected to heavily sustain the VEGF tumour angiogenesis,
since this metal is a potent inducer of VEGF expression and reinforces the stimulating effect
exerted by hydrogen peroxide [82].
The growth of neuroblastoma is anyway sustained by multiple pro-angiogenic factors other
than VEGF [10], including Platelet Derived Growth Factor-A (PDGF-A), Fibroblast Growth
Factor-2 (FGF-2), and Angiopoietin-2 (Ang-2), as documented in 22 neuroblastoma cell lines
and 37 tumour samples [10]. Many among these factors share an intimate relationship with
copper, known to variously enhance their angiogenic action through direct (physical interac‐
tion) or indirect (expression/release) ways.
Neuroblastoma
As an example, the specific binding of copper to angiogenin, a major angiogenic factor, is able
to largely increase its efficiency of interaction with endothelial cells [83,84]. This metal is also
fundamental for the release of another pro-angiogenic factor involved in angiogenesis,
Fibroblast Growth Factor (FGF) 1, as a part of a multiprotein aggregate (FGF1-p40 Syt1-
S100A13) [85].
If on one hand high copper levels can facilitate the tumour development, on the other the
stimulation of copper uptake and egress has been associated with the sprouting of new blood
vessels within solid tumours, this depicting a high complex picture. A prominent role of copper
transport systems emerges.
6.1. Potential role of ATP7A and Ctr1 copper transporters
Several experimental evidences point to a crucial role of copper in tumour angiogenesis [86].
Its ability to stimulate the endothelial cell proliferation, migration and sprouting mainly
grounds on its role as a powerful inducer/enhancer of the expression of several angiogenic
mediators, including VEGF165 and interleukins [82,87], and a stabilizer of the angiogenin
interaction with its receptor [83]. Surprisingly, well-characterized pro-angiogenic factors as
VEGF165 and bFGF, if administered to microvascular endothelial cell cultures, have been shown
to rapidly promote the relocalization of the intracellular copper stores (about 80-90%) toward
the cell periphery, where the ion efflux occurs, presumably by the ATP7A transport activity
[88]. Such process may result contradictory in the light of the discussed role of copper as a
powerful pro-angiogenic mediator. Nevertheless, this mechanism may be considered “cancer
self-sustaining”, making copper available in the tumour microenvironment (paracrine loop).
In addition, it must be observed that the vascular remodelling and the stimulation of cell
migration depend on the activity of copper-dependent secreted enzymes (Lysil Oxidase, LOX),
so the released metal is probably mostly carried by proteins.
In support of such hypothesis, a report from Ashino et al. (2010) illustrated how the pro-
angiogenic Platelet Derived Growth Factor (PDGF) determines in vascular smooth muscle cells
the translocation of the ATP7A copper transporter from the Trans Golgi Network toward
special membrane domains (lipid rafts), where the pump is essential for the correct release of
copper bound pro-LOX [89]. The authors also demonstrated that the membrane recruitment
of Rac-1, a GTPase involved in the extension of lamellipodia, is dependent on copper and on
the expression of the high affinity importer Ctr1 (Copper Transporter 1), this further confirm‐
ing the existence of a solid link between the tumour metastasis and copper homeostasis.
6.2. Potential role of the cellular prion protein PrPC
To our knowledge, a few data are reported in the literature around the prion protein role in
defining the neuroblastoma aggressiveness. Nevertheless, the substantial expression level
observed within the nervous system, which is further elevated by pathological conditions,
testifies to a possible involvement of prion protein in the nervous response to cell injuries. In
detail, this particular protein may have major implications in modulating the biological
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cascade leading to metastasis in patients with cancer, mainly by virtue of its presumed ability
to sustain cell survival and exert a pro-angiogenic action.
A modest literature discusses a likely role of prion proteins in influencing the angiogenic
processes, given a large disagreement about its actual expression in endothelial cells. In fact,
although prion protein has been detected in the capillaries of the intestinal mucosa and kidney
[90], normal endothelial cells derived from the umbilical cord and other vessels in the adults
do not show detectable prion protein amounts in vivo [91]. However, prion protein seems to
be up regulated in some pathological circumstances, such as in advanced carotid plaques, in
association with the endothelial marker CD105, increasingly expressed in activated endothelia
[92], and in brain tissues affected by ischemia [93,94]. By virtue of the latter studies, prion
protein could reasonably play a key role in brain tumour progression, being the related gene
responsive to the ischemic/hypoxic injury [94]. Accordingly, a neuroprotective action has been
described for prion proteins in this context, based on the following evidences: i. prion protein
is bound to caveolin-1 and, by recruiting Fyn tyrosine kinase, it can activate the signalling
promoting cell survival and angiogenesis events [95]; ii. prion protein co-localizes with the
VEGF receptor 2 (KDR), that indicating that prion protein may have a role in VEGF-driven
angiogenesis [96].
7. Anti-angiogenic therapies target the neuroblastoma copper status: two
examples
7.1. TNP-470
The administration of angiogenic inhibitors has been introduced as a complement to tradi‐
tional therapies, in order to hinder the tumour spread.
Several anti-angiogenic therapeutics have been incorporated into clinical trials. Among them, in
the ‘90s, TNP-470, an angiogenesis inhibitor, has emerged as a promising adjuvant in dormancy
therapies for high-risk neuroblastoma. In particular,  its  effectiveness in arresting hepatic
metastasis of neuroblastoma has been documented in [97] and [98]. In the light of [99], the anti-
angiogenic activity of TNP-470 is reasonably linked to its interference with the hepatic copper
metabolism. In fact, the continuous administration of TNP-470 in both normal and tumour-
bearing rats has been shown to increase the serum copper levels, as a consequence of a limited
hepatic retention [99]. This feature has been associated with a reduced density of hepatic tumour
capillaries [99]. Accordingly, when the administration of TNP-470 was interrupted, angiogene‐
sis was activated and at the same time the serum copper levels fell down [99].
7.2. Retinoids target the ATP7A gene expression
Among the most promising possibilities, retinoids (Vitamin A derivatives) may be of help in
arresting the cancer growth and delaying the occurrence of recurrences, because of their
proven ability to induce cell differentiation and inhibit the VEGF and FGF-2-induced endo‐
thelial activation [100]. Interestingly, a recent report from Bohlken et al. (2009) demonstrated
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that retinoids are able to starve neuroblastoma cells of copper through a significant increase
in the ion efflux processes [60]. In fact, the retinoic acid receptor β (RARβ) up-regulates the
expression of ATP7A copper efflux pump in BE(2)-C and SH-SY5Y human neuroblastoma cell
models, but not in other cell types.
8. Cell copper transporters modulate the neuroblastoma sensitivity to
chemotherapy
Cisplatin-based chemotherapy is commonly employed for neuroblastoma treatment at an
advanced stage [101], but the development of resistance to the drug can affect the therapeutic
efficacy. Highly diversified mechanisms have been proposed to explain this behaviour,
although a definitive understanding has not been achieved. It has been demonstrated that
Cisplatin-resistant neuroblastoma cells undergo an increase in the DNA methyltransferase
activities that would depress the transcription of specific and widely undefined genes [102].
In fact, it is known that an acute Cisplatin administration can alter the genome methylation
status in neuroblastoma cells [103].
Increasing evidences point out a central role of (broad substrate spectrum/specific) drug
transporters to explain the onset of Cisplatin resistance. In detail, Haber et al. (1999) observed
that malignant neuroblastoma forms, carrying the N-myc oncogene amplification, show an up
regulation of the Multidrug Resistance-associated Protein (MRP) gene, associated with a poor
sensitivity to low affinity substrates, including Cisplatin [104].
Interestingly, it has been widely demonstrated that Cisplatin shares with copper the pathways
of cellular efflux and entry [105,106]. In particular, the cellular uptake of cisplatin (water
soluble) is mediated by a member of the SLC (Solute Carrier) group, namely the copper
transporter 1 (SLC31A1) [105-107], by mechanisms that partially overlap with those copper-
specific [105,108]. Candidate Cisplatin-binding sequences have been identified in the extrac‐
ellular region of hCtr1, this providing further evidence of the Cisplatin transport activity by
this channel [109].
Further, the copper efflux transporters, ATP7A and ATP7B, are known to regulate the efflux
of cisplatin, and so their expression may be also predictive of drug sensitivity [110].
Neuroblastoma cells are known to express both hCtr1 import and ATP7A export proteins, this
suggesting that copper transport systems may participate in determining the development of
cisplatin resistance. In support of such hypothesis, a recent study on microRNAs expression
pattern in variously N-myc amplified and cisplatin resistant neuroblastoma cells, led to the
identification of eight microRNAs, each one targeting at least one of the two cited copper
transporters [111]. Furthermore, it has been demonstrated that ATP7A expression may be a
target to sensitize cancer cells to Cisplatin [112].
In the light of these findings, it has been argued that an increased cisplatin sensitivity may
arise from the upregulation of Ctr1 transporter or by downregulation of the copper/cisplatin
efflux transporter ATP7A. In this sense, a therapeutic regimen combining a preconditioning
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by a copper chelating agent (i.e. Tetrathiomolybdate) and platinum-containing drugs has been
proven to enhance the Cisplatin efficacy in a mouse model of cervical cancer, without affecting
the integrity of healthy tissues [113].
Another copper-dependent mechanism of resistance to cisplatin involves metallothioneins, a
family of low molecular weight copper-binding proteins, whose expression is metal-induced
in neuroblastoma cell models [114] and elevated in cisplatin-resistant cell lines [115]. When
cisplatin enters a cancer cell, it is vulnerable to metallothionein-inactivation [116]. This
mechanism assumes a prioritary connotation if we consider that N-myc amplified neuroblas‐
tomas show an increased copper content, that translates in a remarkable induction of metal‐
lothioneins and reduced efficacy of Cisplatin-based therapies.
9. Conclusion
Multifaceted pathophysiological features determine the progression of neuroblastoma
malignancies. Mainly on the basis of in vitro and pre-clinical studies, copper, playing a key role
within the human nervous system, is candidate to be the actual target of novel therapies.
Accordingly, high copper levels seem to underline the development of tumour malignancies,
even if we honestly observe that the scientific literature does not offer so many clear cues about
the nature of in vivo copper involvement in neuroblastoma. The conclusive impression is that
copper interacts with the neuroblastoma microenvironment at various levels, and the effects
may be profoundly different, depending on the interested cell type (e.g. endothelial, neuro‐
blast). The overall effects arise from the sum of specific and sometimes discordant copper-
driven processes.
If few clinical data are currently available in this regard, the challenge toward the development
of a copper-targeting therapy has anyway been launched. On the other hand, recent studies
have recognized for neuroblastoma patients the benefits of preconditioning therapies based
on the use of copper chelating agents (i.e. tetrathiomolibdate). Such intriguing approach would
modulate the expression and/or subcellular localization of copper transport systems, and so
both the cancer metal levels and chemoresistance. However, caution is needed in this sense,
since the comprehension of copper metabolism in neuroblastoma cancer cells is still prelimi‐
nary and the routes of copper transport are currently partially known. Significantly, it is only
recently that an anion exchanger has been proposed as an additional copper importer in
mammalian cells [117].
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